Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy

Retargeting the antigen-binding specificity of T cells to intracellular antigens that are degraded and presented on the tumor surface by engineering chimeric antigen receptor (CAR), also named TCR-like antibody CAR-T, remains limited. With the exception of the commercialized CD19 CAR-T for hematolog...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Immunol Res
Asıl Yazarlar: Zhu, Lichen, Yang, Xiaomei, Zhong, Dani, Xie, Shenxia, Shi, Wei, Li, Yangzi, Hou, Xiaoqiong, HuaYao, Zhou, Huihui, Zhao, Minlong, Ding, Ziqiang, Zhao, Xinyue, Mo, Fengzhen, Yin, Shihua, Liu, Aiqun, Lu, Xiaoling
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Hindawi 2020
Konular:
Review Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7492946/
https://ncbi.nlm.nih.gov/pubmed/32964055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/2454907
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller